Skip to main content

Table 2 Multivariate regression analysis to predict relapse during the 12 months after discontinuation of biologic disease-modifying antirheumatic drug therapy

From: Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled

 

Comparison

OR

95% CI

p Value

Sex

Female vs. male

0.25

0.02

1.79

0.17

SDAI at initiation of bDMARD

1 increase

0.95

0.88

1.03

0.20

Bone erosion by ultrasound

Presence vs. absence

8.35

1.78

53.2

0.017

  1. bDMARD Biologic disease-modifying antirheumatic drug; SDAI Simplified Disease Activity Index
  2. Variables with a p value less than 0.02 in Table 1 were used in multivariate models